Imugene Limited (AU:IMU) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Imugene Limited has secured confirmation of an $11 million R&D tax refund from the Australian Taxation Office, expected in January 2025. This refund will bolster the company’s efforts in advancing its cutting-edge immuno-oncology pipeline, aimed at transforming cancer treatment. Imugene’s innovative therapies are poised to make significant impacts in the global cancer treatment market.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
